SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma’s arm gets UK MHRA approval for Cetirizine Dihydrochloride

20 Nov 2025 Evaluate

Marksans Pharma’s wholly owned subsidiary -- Relonchem in the UK, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution.

Earlier, the company’s wholly owned subsidiary -- Marksans Pharma Inc had received the final approval for Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).

Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.


Marksans Pharma Share Price

276.85 13.35 (5.07%)
09-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2502.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: